Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
The deal strengthens AstraZeneca's cancer immunotherapy pipeline during Pascal Soriot's strategic R&D restructuring, adding AMP-514 anti-PD-1 and…
Maryland-based Amplimmune was acquired by MedImmune for up to $500M, validating the state's biotech ecosystem and the commercial pull of immuno-oncology…
MedImmune completed the Amplimmune acquisition for $225M upfront plus up to $275M in milestones, gaining AMP-514 (anti-PD-1) and a B7-pathway pipeline to…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
MedImmune (AstraZeneca) to acquire Amplimmune for $225M upfront + up to $275M dev milestones (total $500M); strengthened immune-mediated cancer therapy portfolio with anti-PD-1 mAb AMP-514 and B7-family programs.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Amplimmune Inc. (this deal) | 2013 | $500M | 21 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2013 deals · AstraZeneca PLC deals · Oncology deals